URGN — UroGen Pharma Ltd.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1668243 ·
Last close
$41.35
Market Cap
$2.02B
52W High
$50.81
52W Low
$15.86
ADV30
799,460
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 72,456,000 | 65,884,000 | 111,000 | -14,351,000 | 252,590,000 | 79,133,000 | 384,986,000 |
| Mar 2026 | 50,959,000 | 46,820,000 | -20,263,000 | -23,574,000 | 253,690,000 | 109,968,000 | 377,943,000 |
| Dec 2025 | 37,837,000 | 34,548,000 | -19,115,000 | -26,364,000 | 200,455,000 | 110,745,000 | 305,929,000 |
| Sep 2025 | 27,482,000 | 24,204,000 | -27,386,000 | -33,347,000 | 185,046,000 | 90,039,000 | 300,454,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-158,917,000
Investing CF
$40,100,000
Financing CF
$105,292,000
CapEx
$-218,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.98
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-997,641,000
Inventory
$24,589,000
Receivables
$88,757,000
ST Investments
$28,842,000
EBIT TTM
$-81,891,000
Pretax Income TTM
$-98,108,000
Interest Exp TTM
$16,217,000
Analysts
8
Yahoo Snapshot (yfinance, live)
Total Revenue
$188,734,000
EBITDA
$-66,345,000
Free Cash Flow
$-106,975,752
Enterprise Value
$2,156,289,536
Total Cash
$107,975,000
Total Debt
$196,128,000
Shares Out
48,880,564
Trailing EPS
$-1.97
Book Value
$-2.71
ROE
—
ROA
-18.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 109,788,000 | -124,863,000 | -153,494,000 | 200,455,000 | 305,929,000 | -105,474,000 | -162,444,000 |
| Dec 2024 | 90,398,000 | -96,782,000 | -126,874,000 | 285,711,000 | 294,514,000 | -8,803,000 | -96,766,000 |
| Dec 2023 | 82,713,000 | -65,536,000 | -102,244,000 | 178,311,000 | 243,523,000 | -65,212,000 | -76,376,000 |
| Dec 2022 | 64,357,000 | -79,041,000 | -109,783,000 | 135,619,000 | 224,980,000 | -89,361,000 | -87,559,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$2.79
Max Pain — expiry 2026-11-20
max pain strike: $40.00 · spot: $41.12 · call oi: 1,681 · put oi: 342
Expected Move to 2026-11-20:
±$9.12
(22.19%) —
implied range
$31.99 –
$50.24
· ATM straddle on $41.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NUVB | Nuvation Bio Inc. | $2.01B | $5.74 | — |
| PVLA | PALVELLA THERAPEUTICS, INC. | $1.99B | $138.16 | — |
| TRVI | Trevi Therapeutics, Inc. | $2.05B | $14.41 | — |
| SRPT | Sarepta Therapeutics, Inc. | $1.97B | $18.67 | — |
| BHVN | Biohaven Ltd. | $1.96B | $12.99 | — |
News headlines (Yahoo Finance, 1h cache)
UroGen Pharma (URGN) Stock Looks Fairly Valued On Its Sales Base
2026-09-25 07:09 · Yahoo
Is UroGen’s (URGN) Commercial Engine Strong Enough To Fund Its Pipeline Ambitions?
2026-09-23 13:13 · Yahoo
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-09-04 12:00 · Yahoo
Wall Street Analysts Think Urogen Pharma (URGN) Could Surge 27.14%: Read This Before Placing a Bet
2026-08-21 13:55 · Yahoo
IntraGel Therapeutics and UroGen Pharma Sign Strategic Collaboration and Investment Agreements to Advance Sustained-Released Investigational Oncology Therapies
2026-08-20 11:05 · Yahoo
UroGen Announces Strategic Collaboration and Investment Agreements with IntraGel to Access Biodegradable Sustained-Release Gel Platform and Expand Oncology Pipeline
2026-08-20 11:00 · Yahoo
UroGen (URGN) Q2 2026 Earnings Call Transcript
2026-08-12 18:15 · Yahoo
Why UroGen Pharma (URGN) Is Up 22.8% After Q2 2026 Revenue Nearly Tripled And Losses Narrowed
2026-08-09 16:12 · Yahoo
UroGen Pharma Ltd (URGN) (Q2 2026) Earnings Call Highlights: Cysview Revenue Surges 73% as Net ...
2026-08-05 21:07 · Yahoo
Urogen Pharma Q2 Earnings Call Highlights
2026-08-05 20:04 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.